In yesterday’s Wall Street session, Navidea Biopharmaceuticals Inc. (AMEX:NAVB) shares traded at $0.12, down -1.67% from the previous session.
1 analysts cover Navidea Biopharmaceuticals Inc. (AMEX:NAVB), according to research data. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $8.00 and a low of $8.00, we find $8.00. Given the previous closing price of $0.12, this indicates a potential upside of 6566.67 percent. NAVB stock price is now 10.88% away from the 50-day moving average and -48.07% away from the 200-day moving average. The market capitalization of the company currently stands at $11.59M.
The stock has received a hold rating from 0 analysts and a buy rating from 1. Brokers who have rated the stock have averaged $8.00 as their price target over the next twelve months.
With the price target reduced from $3 to $2, Aegis Capital maintained Hold rating for Navidea Biopharmaceuticals Inc. (AMEX: NAVB).
A total of 26.30% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in NAVB stock. A new stake in Navidea Biopharmaceuticals Inc. shares was purchased by MILLENNIUM MANAGEMENT LLC during the first quarter worth $15,000. In the first quarter, ROYAL BANK OF CANADA acquired a new stake in Navidea Biopharmaceuticals Inc. valued at approximately,000. In total, there are 30 active investors with 4.70% ownership of the company’s stock.
On Wednesday morning Navidea Biopharmaceuticals Inc. (AMEX: NAVB) stock kicked off with the opening price of $0.1200. During the past 12 months, Navidea Biopharmaceuticals Inc. has had a low of $0.07 and a high of $0.71. The fifty day moving average price for NAVB is $0.1054 and a two-hundred day moving average price translates $0.2269 for the stock.
The latest earnings results from Navidea Biopharmaceuticals Inc. (AMEX: NAVB) was released for Mar, 2023.
